Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders (2016 - 2025)

Collegium Pharmaceutical has reported Net Income towards Common Stockholders over the past 10 years, most recently at $17.0 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at $17.0 million for Q4 2025, up 35.31% from a year ago — trailing twelve months through Dec 2025 was $62.9 million (down 9.13% YoY), and the annual figure for FY2025 was $62.9 million, down 9.13%.
  • Net Income towards Common Stockholders for Q4 2025 was $17.0 million at Collegium Pharmaceutical, down from $31.5 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for COLL hit a ceiling of $74.0 million in Q2 2021 and a floor of -$25.0 million in Q4 2021.
  • Median Net Income towards Common Stockholders over the past 5 years was $12.3 million (2024), compared with a mean of $11.5 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 459.79% in 2021 and later soared 4415.1% in 2023.
  • Collegium Pharmaceutical's Net Income towards Common Stockholders stood at -$25.0 million in 2021, then surged by 71.24% to -$7.2 million in 2022, then skyrocketed by 543.67% to $31.9 million in 2023, then crashed by 60.75% to $12.5 million in 2024, then soared by 35.31% to $17.0 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were $17.0 million (Q4 2025), $31.5 million (Q3 2025), and $12.0 million (Q2 2025) per Business Quant data.